TP53 and cancer: In the DETECT‐A study, a multi‐cancer early detection model combining mutations and proteins, 50% (3/6) of ovarian cancer and 50% (1/2) of uterine cancer exhibited TP53 mutations, aligning with the sensitivity of mutations in our study, ≈50%.[14] Therefore, after a comprehensive comparison, cfDNA methylation, not ctDNA mutation, was chosen as the primary component of the early detection model.